200,000+ products from a single source!
sales@angenechem.com
124192-86-5 | 1H-Inden-1-amine, 2,3-dihydro-N-methyl-N-2-propyn-1-yl-, (1S)-
CAS No: 124192-86-5 Catalog No: AG000LNO MDL No:MFCD07367856
Product Description
Catalog Number:
AG000LNO
Chemical Name:
1H-Inden-1-amine, 2,3-dihydro-N-methyl-N-2-propyn-1-yl-, (1S)-
CAS Number:
124192-86-5
Molecular Formula:
C13H15N
Molecular Weight:
185.2649
MDL Number:
MFCD07367856
IUPAC Name:
(1S)-N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
InChI:
InChI=1S/C13H15N/c1-3-10-14(2)13-9-8-11-6-4-5-7-12(11)13/h1,4-7,13H,8-10H2,2H3/t13-/m0/s1
InChI Key:
CSVGVHNFFZWQJU-ZDUSSCGKSA-N
SMILES:
C#CCN([C@H]1CCc2c1cccc2)C
UNII:
14885LHF9G
Properties
Complexity:
237
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
185.12g/mol
Formal Charge:
0
Heavy Atom Count:
14
Hydrogen Bond Acceptor Count:
1
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
185.27g/mol
Monoisotopic Mass:
185.12g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
3.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.3
Literature
| Title | Journal |
|---|---|
| Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro. | International journal of pharmaceutics 20121115 |
| Rasagiline: a guide to its use in Parkinson's disease. | CNS drugs 20120901 |
| Proteoliposome-based capillary electrophoresis for screening membrane protein inhibitors. | Journal of chromatographic science 20120801 |
| Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. | The International journal of neuroscience 20120701 |
| Drugs for treating Parkinson disease. | Nursing 20120701 |
| Development of Parkinson's disease in patients with Narcolepsy. | Journal of neural transmission (Vienna, Austria : 1996) 20120601 |
| Hyposmia in Parkinson's disease. | Psychiatry and clinical neurosciences 20120601 |
| Livedo reticularis associated with rasagiline (azilect). | Journal of drugs in dermatology : JDD 20120601 |
| The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? | Journal of clinical pharmacology 20120501 |
| Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). | Bioorganic & medicinal chemistry 20120501 |
| Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. | Journal of neural transmission (Vienna, Austria : 1996) 20120401 |
| Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. | Drugs 20120326 |
| Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. | Retina (Philadelphia, Pa.) 20120301 |
| Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. | European journal of neurology 20120201 |
| From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. | Journal of Alzheimer's disease : JAD 20120101 |
| Restless legs syndrome responsive to rasagiline treatment: a case report. | Clinical neuropharmacology 20120101 |
| Combined beneficial effect of rasagiline on motor function and depression in de novo PD. | Clinical neuropharmacology 20120101 |
| Drugs in traffic: the road to approval. | Nature medicine 20111206 |
| Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. | European journal of neurology 20111201 |
| Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. | Movement disorders : official journal of the Movement Disorder Society 20111201 |
| Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. | European journal of pharmacology 20111130 |
| Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. | Movement disorders : official journal of the Movement Disorder Society 20111101 |
| Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. | The neurologist 20111101 |
| An effective novel delivery strategy of rasagiline for Parkinson's disease. | International journal of pharmaceutics 20111031 |
| Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review. | The International journal of neuroscience 20110901 |
| The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. | Movement disorders : official journal of the Movement Disorder Society 20110815 |
| Safety of rasagiline for the treatment of Parkinson's disease. | Expert opinion on drug safety 20110701 |
| TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure. | Circulation. Heart failure 20110701 |
| The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion. | British journal of pharmacology 20110601 |
| Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. | Expert opinion on pharmacotherapy 20110601 |
| A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. | The Lancet. Neurology 20110501 |
| MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. | Journal of proteome research 20110401 |
| Determination of minimal clinically important change in early and advanced Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20110401 |
| Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease? | Antioxidants & redox signaling 20110301 |
| Hemiparkinsonism-hemiatrophy syndrome. | Archives of Iranian medicine 20110301 |
| Rasagiline-induced serotonin syndrome. | Movement disorders : official journal of the Movement Disorder Society 20110301 |
| Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation. | Drugs & aging 20110201 |
| MAO inhibitors. | Cleveland Clinic journal of medicine 20110201 |
| Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats. | Journal of glaucoma 20110101 |
| Selegiline and rasagiline: twins or distant cousins? | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101 |
| Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. | BMC pharmacology 20110101 |
| Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. | Current medicinal chemistry 20110101 |
| [The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101 |
| Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. | International review of neurobiology 20110101 |
| Rasagiline in Parkinson's disease. | International review of neurobiology 20110101 |
| Selective inhibitors of monoamine oxidase type B and the 'cheese effect'. | International review of neurobiology 20110101 |
| Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. | Journal of clinical pharmacology 20101201 |
| Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. | Neurochemical research 20101201 |
| The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? | Neurology 20101123 |
| The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? | Neurology 20101123 |
| Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. | Progress in neurobiology 20101101 |
| Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. | Neurochemistry international 20101101 |
| [Rasagiline: effectiveness and protection in Parkinson's disease]. | Revista de neurologia 20101101 |
| [Disease-modifying therapies in PD]. | Rinsho shinkeigaku = Clinical neurology 20101101 |
| Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease. | European journal of neurology 20100901 |
| Isolated delusional syndrome in Parkinson's Disease. | Parkinsonism & related disorders 20100901 |
| Slowing the decline. | Nature 20100826 |
| Rasagiline improves learning and memory in young healthy rats. | Behavioural pharmacology 20100701 |
| Discordant effects of rasagiline doses in Parkinson disease. | Nature reviews. Neurology 20100701 |
| Long-term efficacy of rasagiline in early Parkinson's disease. | The International journal of neuroscience 20100601 |
| Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? | Neurology 20100406 |
| The delayed-start study in Parkinson disease: can't satisfy everyone. | Neurology 20100406 |
| Reply to Drs. Olanow and Rascol. | Neurology 20100406 |
| The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. | Journal of neurochemistry 20100301 |
| [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. | Fortschritte der Neurologie-Psychiatrie 20100301 |
| Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. | Nature reviews. Neurology 20100301 |
| Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. | The American journal of managed care 20100301 |
| Rasagiline in Parkinson's disease. | The New England journal of medicine 20100218 |
| Rasagiline in Parkinson's disease. | The New England journal of medicine 20100218 |
| TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. | The Journal of pharmacology and experimental therapeutics 20100201 |
| Selective MAO-B inhibitors have low potential for the tyramine effect. | Movement disorders : official journal of the Movement Disorder Society 20100115 |
| Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. | Neuro-degenerative diseases 20100101 |
| The role of rasagiline in the treatment of Parkinson's disease. | Clinical interventions in aging 20100101 |
| What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease? | Neuroepidemiology 20100101 |
| Delayed start, rapid solution? | Neuroepidemiology 20100101 |
| Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. | Neuropsychobiology 20100101 |
| Treatment of advanced Parkinson's disease in the United States: a cost-utility model. | Clinical drug investigation 20100101 |
| [Rasagiline is not for all Parkinson disease patients: the ADAGIO study]. | Nederlands tijdschrift voor geneeskunde 20100101 |
| [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101 |
| Mao-B inhibitor know-how: back to the pharm. | Neurology 20091208 |
| Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. | Progress in neuro-psychopharmacology & biological psychiatry 20091113 |
| Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. | Journal of neural transmission (Vienna, Austria : 1996) 20091101 |
| Rasagiline-induced spontaneous ejaculation. | Movement disorders : official journal of the Movement Disorder Society 20091030 |
| A double-blind, delayed-start trial of rasagiline in Parkinson's disease. | The New England journal of medicine 20090924 |
| Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. | Neurotoxicity research 20090801 |
| Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres. | Journal of pharmaceutical and biomedical analysis 20090712 |
| Validation of the freezing of gait questionnaire in patients with Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20090415 |
| MAO-B inhibitor know-how: back to the pharm. | Neurology 20090414 |
| Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. | Neurotoxicity research 20090401 |
| Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20090315 |
| Neuroprotection by rasagiline in thiamine deficient rats. | Brain research 20090223 |
| Mechanisms compensating for dopamine loss in early Parkinson disease. | Neurology 20090217 |
| [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings]. | Ideggyogyaszati szemle 20090130 |
| Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101 |
| Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. | European review for medical and pharmacological sciences 20090101 |
| [Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. | Drugs & aging 20090101 |
| Sleep attack associated to rotigotine. | Clinical neuropharmacology 20090101 |
| Drug selection and timing of initiation of treatment in early Parkinson's disease. | Annals of neurology 20081201 |
| A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. | Movement disorders : official journal of the Movement Disorder Society 20081115 |
| Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115 |
| The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. | Expert opinion on pharmacotherapy 20081101 |
| Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)). | Acta crystallographica. Section C, Crystal structure communications 20081101 |
| Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081001 |
| [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. | Fortschritte der Neurologie-Psychiatrie 20081001 |
| Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. | Hypertension (Dallas, Tex. : 1979) 20080901 |
| TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. | Journal of cardiovascular pharmacology 20080901 |
| Rasagiline in neurodegeneration. | Experimental neurology 20080801 |
| Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. | Journal of neurochemistry 20080601 |
| [Rasagiline in Parkinson's disease]. | Neurologia (Barcelona, Spain) 20080501 |
| Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. | Experimental neurology 20080401 |
| [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301 |
| Rasagiline improves freezing in a patient with primary progressive freezing gait. | Movement disorders : official journal of the Movement Disorder Society 20080215 |
| Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors. | Journal of biomolecular structure & dynamics 20080201 |
| Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. | Journal of neural transmission (Vienna, Austria : 1996) 20080101 |
| [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101 |
| Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. | Pharmacotherapy 20071201 |
| Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. | Annals of the New York Academy of Sciences 20071201 |
| Parkinson disease: an incremental challenge. | South Dakota medicine : the journal of the South Dakota State Medical Association 20071201 |
| Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. | Journal of neurochemistry 20071001 |
| Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. | Neurochemical research 20071001 |
| Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. | Clinical therapeutics 20070901 |
| The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. | Molecular pharmacology 20070601 |
| Rasagiline as a therapy for Parkinson's disease (PD). | The American journal of geriatric pharmacotherapy 20070601 |
| Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. | Neurobiology of disease 20070101 |
| Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. | Journal of neural transmission (Vienna, Austria : 1996) 20070101 |
| Rasagiline: a review of its use in the management of Parkinson's disease. | Drugs 20070101 |
| Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. | Drugs & aging 20070101 |
| Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. | Journal of neural transmission. Supplementum 20070101 |
| Rasagiline (Azilect) for Parkinson's disease. | The Medical letter on drugs and therapeutics 20061204 |
| L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action. | Pharmacology, biochemistry, and behavior 20061201 |
| The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. | Current Alzheimer research 20061201 |
| Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. | The American journal of geriatric pharmacotherapy 20061201 |
| Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. | Journal of the neurological sciences 20061025 |
| Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. | Movement disorders : official journal of the Movement Disorder Society 20061001 |
| Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. | Neurology 20060523 |
| Clinical trials with rasagiline: evidence for short-term and long-term effects. | Neurology 20060523 |
| Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515 |
| [Diagnosis and therapy of idiopathic Parkinson's disease]. | MMW Fortschritte der Medizin 20060515 |
| Safety of rasagiline in elderly patients with Parkinson disease. | Neurology 20060509 |
| Rasagiline improves quality of life in patients with early Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20060501 |
| Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. | The Annals of pharmacotherapy 20060401 |
| Rasagiline -- is there a place for this drug in managing Parkinson's disease? | International journal of clinical practice 20060201 |
| Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. | International journal of clinical practice 20060201 |
| Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. | British journal of pharmacology 20060101 |
| Concerning neuroprotective therapy for Parkinson's disease. | Journal of neural transmission. Supplementum 20060101 |
| Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. | Journal of neural transmission. Supplementum 20060101 |
| New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| New drug treatment for Parkinson's disease. | FDA consumer 20060101 |
| Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. | Journal of neural transmission. Supplementum 20060101 |
| The use of rasagiline in Parkinson's disease. | Journal of neural transmission. Supplementum 20060101 |
| Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. | Journal of medicinal chemistry 20051229 |
| Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20051101 |
| Present and future drug treatment for Parkinson's disease. | Journal of neurology, neurosurgery, and psychiatry 20051101 |
| Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. | Expert review of neurotherapeutics 20051101 |
| Rasagiline in the pharmacotherapy of Parkinson's disease--a review. | Expert opinion on pharmacotherapy 20051001 |
| In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001 |
| [Rasagiline in motor fluctuations]. | Fortschritte der Neurologie-Psychiatrie 20050901 |
| Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. | Journal of neural transmission (Vienna, Austria : 1996) 20050801 |
| Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. | Journal of clinical pharmacology 20050801 |
| Reexamination of the TEMPO Study. | Archives of neurology 20050801 |
| Rasagiline. | Nature reviews. Drug discovery 20050801 |
| Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. | Annals of the New York Academy of Sciences 20050801 |
| [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. | Medizinische Monatsschrift fur Pharmazeuten 20050701 |
| Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. | Drugs of today (Barcelona, Spain : 1998) 20050601 |
| Parkinson's disease. Diagnosis and the initiation of therapy. | Minerva medica 20050601 |
| Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. | Movement disorders : official journal of the Movement Disorder Society 20050501 |
| Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. | Brain research. Brain research reviews 20050401 |
| Novel pharmacological strategies for motor complications in Parkinson's disease. | Expert opinion on investigational drugs 20050401 |
| Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. | Neuropharmacology 20050301 |
| Rasagiline for motor complications in Parkinson's disease. | Lancet (London, England) 20050301 |
| Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. | Lancet (London, England) 20050301 |
| Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. | Mechanisms of ageing and development 20050201 |
| A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. | Archives of neurology 20050201 |
| Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. | Journal of neuroscience research 20050101 |
| Movement disorders: understanding clinical trials. | The Lancet. Neurology 20050101 |
| Rasagiline. | Drugs & aging 20050101 |
| Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. | Movement disorders : official journal of the Movement Disorder Society 20050101 |
| Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? | CNS drug reviews 20050101 |
| [The early therapy challenge]. | Krankenpflege Journal 20050101 |
| [Are there innovations in the treatment of Parkinson's disease?]. | Praxis 20041103 |
| Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. | Neurology 20041012 |
| Clinical trials of neuroprotection for Parkinson's disease. | Neurology 20041012 |
| Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. | British journal of pharmacology 20041001 |
| Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. | Journal of neural transmission (Vienna, Austria : 1996) 20041001 |
| Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. | Pharmacotherapy 20041001 |
| Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040901 |
| Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. | Journal of neurology 20040901 |
| Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. | Movement disorders : official journal of the Movement Disorder Society 20040801 |
| Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig. | Neuropharmacology 20040701 |
| Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. | Experimental neurology 20040601 |
| Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. | Journal of neurochemistry 20040601 |
| N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. | Neurochemistry international 20040501 |
| A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. | Archives of neurology 20040401 |
| Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. | Journal of medicinal chemistry 20040325 |
| Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. | Journal of medicinal chemistry 20040325 |
| Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. | Neuroscience letters 20040130 |
| Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? | BioEssays : news and reviews in molecular, cellular and developmental biology 20040101 |
| The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031201 |
| The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. | Biochemical pharmacology 20031015 |
| Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. | Annals of the New York Academy of Sciences 20030501 |
| Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline. | Journal of enzyme inhibition and medicinal chemistry 20030401 |
| Monoamine oxidase inhibitors--is it time to up the TEMPO? | The Lancet. Neurology 20030301 |
| A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. | Archives of neurology 20021201 |
| Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. | Neuropharmacology 20021201 |
| Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. | Journal of medicinal chemistry 20021121 |
| Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021001 |
| Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. | Journal of neurochemistry 20020801 |
| Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. | Movement disorders : official journal of the Movement Disorder Society 20020701 |
| An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. | Neuroscience letters 20020628 |
| Rasagiline. Teva Pharmaceutical. | Current opinion in investigational drugs (London, England : 2000) 20020501 |
| Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. | Journal of neural transmission (Vienna, Austria : 1996) 20020501 |
| Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. | Mechanisms of ageing and development 20020430 |
| The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. | Journal of neural transmission (Vienna, Austria : 1996) 20020401 |
| Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. | Parkinsonism & related disorders 20020301 |
| Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. | Cellular and molecular neurobiology 20011201 |
| Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. | Journal of neurochemistry 20010801 |
| Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. | Annals of the New York Academy of Sciences 20010601 |
| Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. | Annals of the New York Academy of Sciences 20010601 |
| The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. | Annals of the New York Academy of Sciences 20010601 |
| Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. | Annals of the New York Academy of Sciences 20010401 |
| Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. | British journal of pharmacology 20010101 |
| Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. | Journal of neural transmission. Supplementum 19980101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.